Follow the Phreesia, Inc. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Phreesia, Inc. has logged 476 public disclosures. Market capitalisation: €658.9m. The latest transaction was disclosed on 7 July 2026 (Cession). Among the most active insiders: Linetsky David. All data is accessible without an account.
Analysts rate Phreesia, Inc. Buy (bullish), based on 17 analysts. Average price target: US$13.94.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 476 declarations
Phreesia, Inc. (ticker: PHR) is a U.S.-listed healthcare technology company trading on the NYSE in the United States. Founded in 2005, the company was built around a clear mission: help patients play a more active role in their care while improving the operational efficiency of healthcare providers. Over time, Phreesia has evolved into a recognized healthcare SaaS platform focused on patient intake, patient activation, payments, and workflow automation for provider organizations. The company’s core platform is designed to digitize and streamline many of the administrative steps surrounding a patient visit, including registration, scheduling, payments, intake questionnaires, and selected clinical support workflows. Phreesia serves thousands of provider organizations across the U.S., giving it a meaningful national footprint in healthcare software. Management has stated that the platform supports roughly 180 million patient visits annually, which suggests significant scale and recurring usage across a broad client base. From a competitive standpoint, Phreesia operates in an attractive but highly competitive niche that sits at the intersection of healthcare software, patient engagement, and revenue cycle-related solutions. Its market position is supported by an integrated product suite, deep penetration into provider workflows, and the ability to create value across the patient journey rather than through a single point solution. The company’s strategy is centered on expanding adoption within existing clients, adding adjacent capabilities, and strengthening payment-related offerings. Recent developments have been important. In 2025, Phreesia announced the acquisition of AccessOne, a healthcare receivables financing specialist, to broaden its payment solutions portfolio and improve collections capabilities for healthcare providers. This acquisition fits the company’s broader effort to extend its platform from intake and engagement into payment optimization. In recent reporting, management also highlighted improving operating leverage and continued progress toward profitability, which is relevant for investors assessing the company’s transition from growth at all costs toward more disciplined execution. Phreesia also remains a name to watch from a governance and market-signal perspective, as SEC Form 4 insider transaction activity can provide additional insight into management behavior and equity ownership trends. For French-speaking investors, the key takeaways are a durable U.S. healthcare software franchise, a specialized product set, and exposure to long-term digitization in the American healthcare system.